Sun Pharma and Moebius Medical receive Fast Track designation for non-opioid osteoarthritis knee pain treatment MM-II.

Sun Pharma and Moebius Medical have received Fast Track designation from the FDA for MM-II, a non-opioid treatment for osteoarthritis knee pain. This product employs a unique suspension of large liposomes aimed at reducing joint friction and pain. The Fast Track program facilitates quicker review and approval processes for serious conditions. The companies plan to begin Phase 3 trials and pursue a CE Mark in the EU.

September 06, 2024
5 Articles